Skip to content

5-MeO-DMT: all studies

Page 48 of 110: studies 471 to 480 of 1,096, newest first. Back to the 5-MeO-DMT overview

Research

Rewiring Receptor Activation: Mechanistic Insights into Toggle Switch Modulation by 25CN-NBx Compounds

ACS Chemical Neuroscience February 18, 2026 Vito F. Palmisano, Micaela Vidal−sánchez, Juan J. Nogueira

High Resolution Image Download MS PowerPoint Slide The development of new treatments for neuropsychiatric disorders relies on a deeper understanding of the molecular mechanisms behind psychedelic compounds, particularly how they differentiate between hallucinogenic and antidepressant effects. In this study, we explore by molecular dynamics simulations a series of 25CN-NBx compounds bound to the...

DOI: 10.1021/acschemneuro.6c00023 (opens in new tab) Dihedral angle Molecular dynamics Receptor Molecular mechanics +4

Ischemia-Induced Neurodegeneration in Glaucoma: Mechanistic Insights and Translational Opportunities for Psychoplastogen-Based Therapies

Pharmaceuticals February 14, 2026 Petra Dolenec, Goran Pelčić, Kristina Pilipović et al.

Glaucoma is increasingly recognized as an ischemic neurodegenerative disorder that extends beyond elevated intraocular pressure (IOP) to involve complex vascular, metabolic, and inflammatory mechanisms. Retinal ganglion cells are particularly vulnerable to ischemia-reperfusion injury, oxidative stress, and chronic neuroinflammation, leading to progressive disconnection from central visual...

When Time Stops: Inside the Mind's Clock

Zenodo (CERN European Organization for Nuclear Research) February 8, 2026 Eugene Catrambone preprint

When Time Stops: Inside the Mind’s Clock is a theoretical preprint monograph exploring how subjective time perception may relate to brain dynamics, informational complexity, and cytoskeletal processes. The work introduces the Scalar Clock Model, in which subjective duration is represented by a scalar variable (φ) whose accumulation rate may be influenced by large-scale neural activity and...

Ayahuasca modulation of traumatic-like fear memories requires infralimbic cortex BDNF-dependent mechanisms in rats.

European Neuropsychopharmacology February 1, 2026 Isabel Werle, Francisco S Guimarães, Rafael G. Dos Santos et al.

Rodent studies have shown that psychedelic drugs can enhance fear extinction. However, investigations to date have relied on normative aversive conditioning procedures, which limit their relevance to trauma-related memories, as these tend to be overgeneralized and resistant to extinction. Fear extinction depends on activity and plasticity within the infralimbic (IL) region of the medial...

Psychedelics and the Extracellular Matrix: Rewiring Neuroplasticity and Metaplasticity for Next-Generation Psychiatric Therapies

Biological Psychiatry February 1, 2026 Jin Zhang, Cong Lin, Xinyou Lv et al. 1 citation

Classic psychedelics, such as psilocybin, lysergic acid diethylamide (LSD), and N,N-dimethyltryptamine (DMT), have emerged as potent modulators of neuroplasticity and metaplasticity in the adult brain, offering novel therapeutic strategies for neuropsychiatric disorders. Recent findings reveal that beyond their transient psychotropic effects, these compounds activate serotonin 5-HT2A receptors...

The Last Dream: A Neurocognitive Model of Terminal Brain Activity and Subjective Time at Death

Zenodo (CERN European Organization for Nuclear Research) January 29, 2026 Sciacchitano Gianluca preprint

This preprint presents The Last Dream, a theoretical model aimed at interpreting the subjective experience that may occur in the seconds immediately following cardiac arrest and preceding irreversible neuronal failure. Drawing on convergent evidence from physics of time, neuroscience, neurochemistry, and psychedelic research, the model explores the plausibility of a transient terminal state...

Single-dose DMT reverses anhedonia and cognitive deficits via restoration of neurogenesis in a stress-induced depression model.

Translational Psychiatry January 29, 2026 Rafael V Lima Da Cruz, Rêmullo B. G. De Miranda Costa, Gabriel M. De Queiroz et al. 2 citations

Major depressive disorder (MDD) remains a leading cause of disability worldwide, with current treatments limited by delayed onset and low efficacy. The serotonergic psychedelic N,N-dimethyltryptamine (DMT) has shown rapid antidepressant effects in early clinical studies, yet its mechanisms and efficacy remain poorly characterized in established models of depression. Here, we evaluated the...

Psilocybin and the Evolutionary Significance of Altered Neural States: Interaction-Based Perspectives Beyond Deterrence Models

January 28, 2026 Philip Rebensburg

Psilocybin is a psychoactive tryptamine produced by a phylogenetically discontinuous yet ecologically diverse subset of fungi. Despite decades of chemical, pharmacological, and ethnobiological research, the evolutionary forces driving the emergence and persistence of this compound remain insufficiently explained. Recent hypotheses proposing that psilocybin evolved primarily as a deterrent...

DOI: 10.32942/x2v66q (opens in new tab) Psilocybin Convergent evolution Mechanism biology Relevance law +3

Safety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive Substances: Potential Drug Interactions and Substance Use Disorder Treatment Data.

CNS Drugs January 17, 2026 Gaëlle Rached, Anna Campana, Dimitri Fiani et al. 1 citation

Monoamine oxidase inhibitors (MAOIs) remain an important option for patients with treatment-resistant depression (TRD) and other psychiatric conditions, despite potentially serious drug-drug interactions and associated dietary tyramine restrictions. However, they are rarely prescribed in patients with comorbid substance use disorders (SUDs) due to concerns about potential drug interactions and...

Psychedelics and music: characterising changes in hierarchy of brain dynamics among the Santo Daime

Oxford University Research Archive (ORA) (University of Oxford) 2026 K Jerotic

The last few decades have been characterised by a resurgence in research and clinical interest in classic serotonergic psychedelics including N,N-dimethyltryptamine (DMT), lysergic acid diethylamide (LSD) and psilocybin, with a growing body of literature pointing to their treatment potential. Ayahuasca is a psychedelic brew commonly composed of plants carrying the psychoactive compound DMT, and...